SCHEMBL3598191

SCHEMBL3598191

Cc1sc(NC(=N)N)nc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.63
XIAP P98170 1/20 0.63
GSTO1 P78417 1/20 0.60
ALDH1A1 P00352 6/20 0.59
HSD17B10 Q99714 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
MAPK1 P28482 1/20 0.58
MAOA P21397 7/20 0.57
MAOB P27338 7/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
MAPT P10636 4/20 0.57
RAB9A P51151 3/20 0.56
LMNA P02545 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
PKM P14618 1/20 0.56
NPC1 O15118 2/20 0.55
HPGD P15428 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606192 0.87 PLTP (0.56) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL3604783 0.85 ALDH1A1 (0.48) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL3597492 0.85 DHODH (0.54) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL18215318 0.85 ALOX5 (0.72) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL3598534 0.85 CFTR (0.50) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL3593422 0.85 XIAP (0.47) ALOX5XIAPGSTO1ALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL11260405 0.84 XIAP (0.46) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL10810440 0.81 ALOX5 (0.76) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL3607131 0.81 ATP4A (0.43) ALOX5XIAPGSTO1ALDH1A1HSD17B10
SCHEMBL3609977 0.81 ALDH1A1 (0.64) XIAPALDH1A1HSD17B10CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 ALOX5 3883/4885XIAP 4640/4885GSTO1 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.